Oncology ASCO 2024 - Matteo Levisetti ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
